Chamber member Exscientia raises $60 million

Published

27th May 2020

Dundee-based drugs discovery company Exscientia has raised $60 million in its latest financing round.

The staggering sum realised by the Dundee University spin-out was led by new investor Novo Holdings, with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital – also participating in the Series C round.

Exscientia, which operates from River Court at City Quay, and Oxford, said the new capital will be used to expand its product pipeline and to launch new products.

Established in 2012 by Professor Andrew Hopkins, the life sciences firm uses artificial intelligence (AI) and machine learning to identify promising compounds for drugs.

It has signed several major drug partnerships with pharma companies worldwide which it believes will be worth more than $1 billion in development milestones and royalties.

To read more on this story, visit The Courier Online 

Exscientia Ltd

At the forefront of small molecule drug discovery. We are the first company to automate drug design, surpassing conventional human endeavour.

Back to news